Brought to you by 
Impax grants GSK rights to PD candidate IPX066; terminated
30 Apr 2013
Executive Summary
Generics company Impax Laboratories Inc.'s branded drug unit Impax Pharmaceuticals has licensed GlaxoSmithKline PLC exclusive worldwide rights to its Phase III Parkinson's disease candidate IPX066. The deal excludes the US and Taiwan.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Impax grants GSK rights to PD candidate IPX066; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice